<PAGE>

                                                                   Exhibit 10.29

          RESOLVER-TM- SYSTEM EARLY ACCESS PROGRAM AND LICENSE AGREEMENT

          This Agreement (hereinafter "Agreement"), effective as of September
30, 1999, (hereinafter "Effective Date") is made by and between DuPont
Pharmaceuticals Company ("DuPont"), a Delaware general partnership, with offices
at Chestnut Run Plaza, 974 Centre Road, Wilmington, Delaware 19805 and Rosetta
Inpharmatics, Inc. ("Rosetta"), a Delaware corporation, with principal offices
at 12040 - 115th Avenue Northeast, Kirkland, Washington 98034.

                                    RECITALS

          1.       DuPont is a worldwide business that focuses on research,
                   development, and delivery of pharmaceuticals to treat unmet
                   medical needs in the fight against AIDS, cardiovascular
                   disease, central nervous system disorders, cancer and
                   arthritis-related disorders.

          2.       Rosetta is developing a new gene expression analysis platform
                   known as the Resolver-TM- System that can be used to
                   interrogate and analyze complex pharmacological effects.

          3.       DuPont desires early access to pre-commercial release
                   versions of the Resolver-TM- System for internal use.

          4.       Rosetta desires feedback on the features and capabilities of
                   the Resolver-TM- System to assist it in the continued
                   development of this system.

                              TERMS AND CONDITIONS

          NOW, THEREFORE, in consideration of the mutual covenants expressed in
this Agreement, DuPont and Rosetta agree as follows:

                             ARTICLE 1-- DEFINITIONS

          1.1 "AGREEMENT" means this agreement and all the attachments hereto.

          1.2 "CONFIDENTIAL INFORMATION" means any Information received by one
party (the Receiving Party) from another party (the Disclosing Party) that is
treated by the Disclosing Party as confidential, provided that such information,
(i) if in written form, is marked "Confidential" or "Proprietary," or (ii) if in
other than written form and although not marked "Confidential" or "Proprietary"
and not otherwise identified by the Disclosing Party as confidential, is of such
a nature that a reasonable person would treat it as confidential or proprietary,
unless such information:

          (a) was known to the Receiving Party prior to receipt from the
Disclosing Party, as shown by appropriate evidence;

*   Material has been omitted pursuant to a request for confidential treatment,
    and such material has been filed separately with the SEC.

<PAGE>

          (b) was lawfully available to the trade or to the public prior to
receipt from the Disclosing Party;

          (c) becomes lawfully available to the trade or to the public after
receipt from the Disclosing Party through no act on the part of the Receiving
Party;

          (d) corresponds in substance to any information received in good faith
by the Receiving Party from any third party without breach of any obligation of
confidentiality; or

          (e) is communicated to any third party by the Disclosing Party without
restriction as to confidentiality or on the basis of a restriction that has
lapsed.

          1.3 "DELIVERABLE" means a specific tangible thing or task identified
in the Agreement as something that must be delivered by one Party to the other,
usually by a date specified in the Agreement, and which may trigger an
obligation upon the part of, or a response by, the recipient.

          1.4 "DISCLOSING PARTY" when used in reference to Confidential
Information means the Party that discloses Confidential Information to the
Receiving Party by furnishing documents or other media containing Confidential
Information, by orally disclosing Confidential Information, or by permitting
visual inspection of something considered confidential.

          1.5 "EARLY ACCESS PROGRAM" OR "PROGRAM" means the arrangement between
the Parties pursuant to this Agreement whereby DuPont has access to the
Resolver-TM- System prior to its commercial release for internal use only, and
provides feedback to Rosetta regarding the Resolver-TM- System together with the
Resolver-TM- Software so that Rosetta can continue its development efforts in
respect thereof.

          1.6 "FEATURE-COMPLETE RELEASE" means a version of the Resolver-TM-
Software that contains all of the features and capabilities that Rosetta will
provide at the beginning of Stage 3. For a description of these features, see
Appendix A, Stage 3. The Feature-Complete Release delivered to DuPont under this
Agreement will be a beta version, i.e., a version that is still undergoing
testing prior to commercial release.

          1.7 "INFORMATION" means business and technical information learned or
received by a Party from or about the other Party prior to and during the term
of this Agreement, and includes, by way of example, the terms of this Agreement,
information relating to products or manufacturing capabilities of any Party,
customer lists, computer programs or other software, user documentation for
software, business methods and plans for future developments, know-how, trade
secrets, inventions, other intellectual property, innovations, improvements,
discoveries, formulae, techniques, processes, approaches, concepts, data,
reports, opinions, blueprints, diagrams, schematics, charts, machines,
specifications, drawings, plans, articles of manufacture, samples, parts lists,
log books, and research reports, as well as requests for quotes, proposals, and
purchase orders.

          1.8 "INITIAL FEATURE RELEASE" means a version of the Resolver-TM-
Software that does


                                      -2-
<PAGE>

not contain all of the features and capabilities of the Feature-Complete
Release. For a description of features that Rosetta will provide with the
Initial Feature Release, see Appendix A, Stage 1.

          1.9 "INTELLECTUAL PROPERTY RIGHTS" shall mean any patents, patent
applications, trademarks, copyrights, know-how, moral rights, and similar rights
of any type under the laws of any governmental authority, domestic or foreign,
including all applications and registrations relating to any of the foregoing.

          1.10 "PARTY" AND "PARTIES" refer to and mean DuPont or Rosetta, as the
context requires.

          1.11 "RECEIVING PARTY" when used in reference to Confidential
Information means the Party that receives Confidential Information from the
Disclosing Party in documents or other media containing Confidential
Information, or orally during a presentation or discussion disclosing
Confidential Information, or through visual inspection of something considered
confidential.

          1.12 "RESOLVER-TM- SOFTWARE" OR "SOFTWARE" means the gene expression
analysis software and database, including its schema, licensed hereunder that is
being developed by Rosetta as part of the Resolver-TM- System and any derivative
works, or any changes, modifications, corrections, improvements, or extensions
to the Software. The Resolver-TM- Software consists of Reso1ver-TM- Server
Software" and one or more copies of Resolver-TM- Client Software.

          1.13 "RESOLVER-TM- CLIENT SOFTWARE" means one or more copies of a
Resolver-TM- Software client application that resides on desktop computers
operated by a user at DuPont.

          1.14 "RESOLVER-TM- SERVER SOFTWARE" means that part of the
Resolver-TM- Software that resides on the Server.

          1.15 "RESOLVER-TM- SYSTEM" as used herein means a system consisting of
the hardware and software components described in Section 4.1.

          1.16 "SECOND FEATURE RELEASE" means a version of the Resolver-TM-
Software that has features in addition to the features available in the Initial
Feature Release, but fewer features than the Feature-Complete Release. For a
description of features that Rosetta will provide with the Second Feature
Release, see Appendix A, Stage 2.
          1.17 "SERVER" shall have the meaning ascribed thereto in Section
4.1.1.

          1.18 "TERM" shall have the meaning ascribed thereto in Section 7.1.

                  ARTICLE 2 -- OVERVIEW OF EARLY ACCESS PROGRAM

         2.1 OVERVIEW OF THE PROGRAM. Rosetta hereby undertakes to provide
DuPont with early access to the Resolver-TM- System and DuPont hereby agrees to
cooperate with Rosetta on development and improvement of the Resolver-TM-
System. The Program will consist of three (3)


                                      -3-
<PAGE>

phases or stages that correspond to delivery of different versions of
Resolver-TM- Software to DuPont. For Stages 1 and 2 of the Program, Rosetta
will provide DuPont with access to the Initial Feature Release and Second
Feature Release, respectively, of the Resolver-TM- Software that will reside
on a Server owned by DuPont and located at Rosetta's premises. DuPont will
access the Resolver-TM- System over a secure connection such as a virtual
private network or a private virtual circuit. Rosetta will deliver, when
available, a beta version of the Feature-Complete Release for Stage 3, which
will likewise initially reside on the Server located at Rosetta's premises and
then be transferred to DuPont's premises. The parties expect that DuPont's
early use of the Resolver-TM- System, together with DuPont's feedback regarding
the performance thereof, will assist Rosetta in the development program for the
Resolver-TM- System and the Resolver-TM- Software, as well as benefit DuPont by
providing early access to a gene expression data analysis solution at a price
less than the anticipated price that will be charged to customers when the
Feature-Complete Release version of the Resolver-TM- System is available. This
Agreement sets out the duties and obligations of each Party for the Early
Access Program.

          2.2 UNFINISHED SOFTWARE. DuPont and Rosetta acknowledge and agree that
the Initial Feature Release, Second Feature Release, and Feature-Complete
Release versions of the Resolver Software will likely contain bugs, defects, and
errors, and that the Software is not expected by either DuPont or Rosetta to
function error-free upon installation. DuPont and Rosetta further acknowledge
and agree that the Resolver-TM- Software is being provided to DuPont on an early
access basis to provide Rosetta with feedback to evaluate and improve its
Resolver-TM- System.

          2.3 EXPECTATIONS OF THE PARTIES. Each of the Parties shall use its
commercial best efforts to perform the tasks that are assigned to it as set
forth in this Agreement.

                    ARTICLE 3 -- LICENSE SCOPE AND MANAGEMENT
                           OF THE EARLY ACCESS PROGRAM

          3.1 LIMITED SOFTWARE LICENSE.

          3.1.1 GRANT OF LICENSE. Subject to full and timely payment of all
amounts due Rosetta under Article 6 and subject to the other terms and
conditions of this Agreement, Rosetta hereby grants DuPont a nonexclusive,
nontransferable, revocable license to use the Software (in object code form
only, and without any right to sublicense or make derivative works or any
changes, modifications, corrections, improvements, or extensions of the
Software) for internal use only in the United States pursuant to the virtual
private network established hereunder to connect DuPont to the Resolver-TM-
System located at Rosetta's premises during Stages 1 and 2, and thereafter
during the Term of this Agreement at DuPont's site [***]. The License includes
only rights under presently existing patents and copyrights and only to the
extent necessary to use the Resolver-TM- Software as delivered and only when
using the Resolver-TM- System as provided by Rosetta. Upon expiration or
termination of this Agreement all rights and licenses granted to DuPont
pursuant to this Agreement with respect to the Resolver-TM- Software shall
revert to Rosetta and DuPont shall retain no rights therein.

         3.1.2 RESTRICTIONS. DuPont agrees that it and its employees,
consultants, and

*   Material has been omitted pursuant to a request for confidential treatment,
    and such material has been filed separately with the SEC.

                                      -4-
<PAGE>

representatives will not directly or indirectly (i) subject to Section 12.5,
sell, lease, assign, sublicense, or otherwise transfer, (ii) duplicate,
reproduce, or copy, (iii) disclose, divulge, or otherwise make available to any
third party, (iv) use except as authorized by this Agreement, or (v) decompile,
disassemble, reverse engineer, or otherwise analyze for reverse engineering
purposes, the Software or any portion thereof, including all trade secrets and
Confidential Information therein. DuPont is granted no title or ownership rights
to the Software, and all such rights shall remain with Rosetta. DuPont shall use
its best efforts to prevent inadvertent disclosure of the Software or any
portion thereof, including all trade secrets and Confidential Information
therein. DuPont shall not permit any third party, nor any employee, consultant,
representative, or agent thereof, that develops, markets, or licenses computer
programs with functionality similar to the functionality of the Software to have
access to the Software or to any trade secrets or Confidential Information
therein. The Resolver-TM- Client Software may be installed on up to [***]
DuPont desktop computers concurrently.

          3.1.3 TERM OF LICENSE. The license to the Software granted by this
Agreement shall expire concurrently with the expiration or termination of this
Agreement as set forth in Article 7.

          3.1.4 DELETION OF SOFTWARE; RETURN OF DOCUMENTATION AND MATERIALS.
As soon as practicable following any termination or expiration of this
Agreement (and in no event more than five (5) business days thereafter),
DuPont shall (i) permit Rosetta to permanently delete (a) the Resolver-TM-
Software from the Server located at Rosetta's premises or such other location
at which a Server on which the Software is loaded is then situated and (b)
the Resolver-TM- Client Software installed on desktop computers at DuPont's
premises, (ii) return to Rosetta all written Information provided by, or on
behalf of, Rosetta to DuPont including, but not limited to, Software
documentation, and (iii) permanently delete or permit Rosetta to permanently
delete any other copies of the Software from all computer systems under
DuPont's control. Upon request by Rosetta, DuPont will certify in writing to
DuPont's compliance with this Section 3.1.4.

          3.2 DESIGNATION OF PROGRAM CONTACT. Each Party shall designate an
appropriate person, and if necessary a replacement, to serve as its contact for
the Program ("Program Contact"). Rosetta's Program Contact initially will be
Doug Bassett, Ph.D., and DuPont's Program Contact [***].

          3.3 RESPONSIBILITIES OF PROGRAM CONTACT. The Program Contacts shall
represent their respective Parties on all business issues pertaining to the
subject matter of this Agreement. The Program Contact shall be the person whom
the other Party contacts initially on all business issues. The Program Contacts
shall be responsible for developing and maintaining communications between the
Parties, determining the status of all activities required or contemplated by
this Agreement, monitoring the other Party's compliance with the provisions of
this Agreement, and generally promoting a healthy relationship between the
Parties. The Program Contacts shall confer as needed to ensure that technical
questions and administrative issues are satisfactorily addressed and resolved.

         3.4 TESTING AND FEEDBACK ON RESOLVER-TM- SYSTEM. On a periodic basis
during Stages 1, 2, and 3 of this Agreement as may be agreed from time to time
between the Program

*   Material has been omitted pursuant to a request for confidential treatment,
    and such material has been filed separately with the SEC.

                                      -5-
<PAGE>

Contacts, b t in no case less than every [***], the Program Contacts or
their designees shall meet or confer to discuss the experience and feedback of
DuPont users regarding the Resolver-TM- System. One week prior to each feedback
session, DuPont's Program Contact will provide Rosetta's Program Contact with a
written summary of the feedback that will be discussed at the meeting.

          3.5 ACCESS TO RESOLVER-TM- SYSTEM. DuPont shall allow Rosetta to have
access to the Resolver-TM- System for the purpose of using, testing, modifying,
and correcting the Software, PROVIDED, HOWEVER, that such access shall not
materially disrupt DuPont's use of the Resolver-TM- System.

          3.6 RIGHT OF ROSETTA TO DUPONT'S FEEDBACK. DuPont agrees that Rosetta
shall have, subject to Article 8, the unlimited right to use without
compensation to DuPont, in any manner and for any purpose, any and all
information about the Resolver-TM- System gained by DuPont as a result of
DuPont's use and evaluation of the Resolver-TM- System. Such information shall
include, but not be limited to, any derivative works, changes, compilations,
modifications, corrections, improvements, and extensions to the Resolver-TM-
System suggested or identified by DuPont. Rosetta shall have the right to use,
at its sole discretion, all such information including, but not limited to, use
by incorporation of such information into computer programs and documentation
for assignment, license, or other transfer to third parties, without any duty
to account to DuPont, and DuPont hereby agrees that it will not assert any
claims against Rosetta or its assignees or sublicenses with respect to
Rosetta's or its assignees' or sublicenses' practice, use, licensing,
manufacturing, marketing, sale or distribution of the Resolver-TM- System or
Software or any product similar to either thereof that incorporates or utilizes
any of such information.

          3.7 NO OBLIGATION TO SUPPORT SOFTWARE. Except as expressly set forth
in Article 5, Rosetta shall have no obligation to correct any bugs, defects, or
errors in the Resolver-TM- System or to otherwise support or maintain the
Software.

          3.8 OWNERSHIP OF RESOLVER-TM- SOFTWARE. DuPont agrees that Rosetta
owns all rights, title, and interest including, but not limited to, Intellectual
Property Rights, in the Resolver-TM- Software and any derivative works, changes,
compilations, modifications, corrections, improvements, or extensions to the
Software and Rosetta has the right to file for or otherwise secure and protect
such rights. If DuPont is ever held or deemed to be the owner of any
Intellectual Property Rights or other rights in the Software or any derivative
works, changes, compilations, modifications, corrections, improvements, or
extensions of the Software, then DuPont hereby irrevocably assigns to Rosetta
all such rights, title, and interest and agrees to execute and deliver all
documents and take such other actions as shall be necessary or advisable to
create and secure all such rights, title, and interest in Rosetta at Rosetta's
sole expense.

          3.9 ROSETTA GENE EXPRESSION DATA PROVIDED WITH RESOLVER-TM- SYSTEM.
Rosetta provides gene expression data with the Reso1ver-TM- System for use in
tutorial sessions. DuPont acknowledges and agrees that Rosetta's gene expression
data are being provided free of charge and without compensation. DuPont agrees
that Rosetta owns all rights, title, and interest including, but not limited to,
Intellectual Property Rights in the gene expression data. DuPont acknowledges
and agrees that such gene expression data are to be used only for internal
tutorial

*   Material has been omitted pursuant to a request for confidential treatment,
    and such material has been filed separately with the SEC.

                                      -6-
<PAGE>

purposes. DuPont agrees that it and its employees, consultants, and
representatives will not, directly or indirectly, (i) subject to Section 12.5,
lend, sell, lease, assign, or otherwise transfer, (ii) duplicate, reproduce, or
copy , (iii) show, disclose, divulge, discuss, or otherwise make available to
any third party, (iv) export or import to another database or software tool, (v)
use except as authorized by this Agreement, or (vi) analyze for research
purposes, Rosetta's gene expression data or any portion thereof, including all
trade secrets and Confidential Information therein. DuPont is granted no title
or ownership rights to the gene expression data, and all such rights shall
remain with Rosetta. Any inventions, discoveries, or Intellectual Property
Rights arising or related to use of these gene expression data shall belong to
Rosetta. If DuPont is ever held or deemed to be the owner of any Intellectual
Property Rights or other rights in any inventions or discoveries based upon
Rosetta's gene expression data, then DuPont hereby irrevocably assigns to
Rosetta all such rights, title, and interest and agrees to execute and deliver
all documents and take such other actions as shall be necessary to carry out and
effectuate the intent of this Agreement. Rosetta hereby grants DuPont a first
right to negotiate an exclusive license for such Intellectual Property Rights
upon terms and conditions to be negotiated between the Parties.

          3.10 DESUPPORT NOTIFICATION. Rosetta will notify DuPont's Program
Contact at least thirty (30) days before support for an old version of the
Software is to be terminated.

          3.11 DUPONT'S [***]. DuPont certifies that it has an [***], and
that this [***] for [***] of this Agreement.

          3.12 DUPONT'S EXPERIMENTAL DATA. In its use of the Resolver-TM-
System, DuPont will be loading experimental data into the Resolver-TM- Software
("DuPont Data"). Rosetta acknowledges and agrees that DuPont Data is
Confidential Information as defined in Section 1.2. Rosetta agrees that DuPont
owns all rights, title, and interest including, but not limited to, Intellectual
Property Rights in the DuPont Data. Rosetta agrees that it and its employees,
consultants, and representatives will not, directly or indirectly, (i) lend,
sell, lease, assign, or otherwise transfer, (ii) duplicate, reproduce, or copy,
(iii) show, disclose, divulge, discuss, or otherwise make available to any third
party, (iv) export or import to another database or software tool, or (v)
analyze for research purposes DuPont Data or any portion thereof, including all
trade secrets and Confidential Information therein. Rosetta is granted no title
or ownership rights to the DuPont Data, and all such rights shall remain with
DuPont.

          3.13 NOTICES. Formal notices required or permitted hereunder shall be
given in writing. Written notices may be delivered personally, sent by first
class mail to the address indicated below, or transmitted electronically by
facsimile transmission ("faxed") to the fax telephone number indicated herein.
All notices or other communications required or permitted hereunder shall be
deemed to have been given (i) if sent by facsimile with confirmed transmission
(accompanied by same day deposit of the original in the U.S. Mail, first-class
postage prepaid, and properly addressed), on the next business day following
facsimile transmission, (ii) if by personal delivery to the proper address, on
the date of such delivery, (iii) if by overnight courier service to the proper
address, on the second business, day following deposit if delivered within the
same country, or on the third business day following deposit if

*   Material has been omitted pursuant to a request for confidential treatment,
    and such material has been filed separately with the SEC.

                                      -7-
<PAGE>

delivered to another country or (iv) if mailed, postage prepaid first class
certified or registered mail, return receipt requested, on the fourth business
day after mailing if mailed within the same country as that of the addressee and
on the seventh business day after mailing if mailed to addressee in another
country, to the address designated below or to such other address as a Party may
designate to the other in writing:

DuPont Pharmaceutical Company                     Rosetta Inpharmatics, Inc.
974 Centre Road                                   12040 - 115th Avenue NE
Wilmington, Delaware 19805                        Kirkland, WA 98304
Attn: [***]                                       Attn: Chief Operating Officer
Fax: (302) 695-9420                               Fax: (425) 820-5757

with a copy to:                                   with a copy to:
DuPont Pharmaceutical Company                     Rosetta Inpharmatics, Inc.
974 Centre Road                                   12040- 115th Avenue NE
Wilmington, Delaware 19805                        Kirkland, WA 98034
Attn: Legal Division                              Attn: Legal Dept.

          ARTICLE 4 -- DESCRIPTION OF RESOLVER-TM- SYSTEM AND CONNECTION

          4.1 RESOLVER-TM- SYSTEM. The Resolver-TM- System consists of the
hardware and software components described in this Section 4.1.

          4.1.1 SERVER.

          4.1.1.1 HARDWARE. The hardware upon which the Resolver-TM- Server
Software will be initially loaded is a Sun EnterpriseTM "35xx" server that will
include two (2) central processing units "(CPU"), four (4) gigabytes of random
access memory, one A5200 drive array that has two hundred (200) gigabytes of
capacity, and an Ll000 tape backup device that has one (1) terabyte of capacity.
Configuration of the Server and any modifications to the Server during Stages 1
and 2 must be conducted or authorized by Rosetta for the Resolver-TM- System to
qualify for the maintenance and support set forth in Article 5. Any
modifications to the Server hardware or Server software during Stages 1, 2, or 3
of this Agreement that are not approved in writing by Rosetta will cancel
Rosetta's obligations for providing maintenance and support as set forth in
Article 5.

         4.1.1.2 OWNERSHIP OF HARDWARE. Rosetta agrees to sell and DuPont agrees
to purchase the [***]. Rosetta and DuPont hereby confirm their intent that the
Server shall be deemed property of DuPont even though it may become attached
or affixed to realty on the premises of Rosetta, and title thereto shall
remain in DuPont or its assigns exclusively. DuPont may require plates or
markings to be affixed to the Server indicating DuPont's interest. While the
Server is on Rosetta's property and in its possession, Rosetta shall be
responsible therefor, and shall protect DuPont against any loss of, or damage
to such property through insurance coverage with limits and terms and
conditions satisfactory to DuPont. [***]

*   Material has been omitted pursuant to a request for confidential treatment,
    and such material has been filed separately with the SEC.

                                      -8-
<PAGE>

          4.1.1.3 SERVER SOFTWARE. The Server will be loaded with the
following non-Rosetta commercial software applications as well as other
applications deemed necessary by Rosetta for the Resolver-TM- System: (1)
[***], (2) [***], (3) [***], (4) [***], and (5) [***].

          4.1.2 RESOLVER-TM- SOFTWARE. The Server will be loaded with the
applicable version of Rosetta's Resolver-TM- Server Software and software for
installation of the Resolver -TM- Client Software on compliant DuPont desktop
computers.

          4.2 LOCATION OF RESOLVER-TM- SYSTEM. During Stages 1 and 2 as
described in Article 5, the Resolver-TM- System will be on the premises of
Rosetta to assist in the maintenance of the system. During Stage 3, the parties
expect that the Resolver-TM- System will be relocated to a location specified
by DuPont. Rosetta and DuPont may mutually agree to move the Server to DuPont's
premises prior to Stage 3.

          4.3 SERVER HARDWARE UPGRADES. Rosetta recognizes that after the
initiation of Stage 1 of the Program, DuPont may want to upgrade the Server by,
for example, installing additional CPUs or additional memory to increase the
performance of the Resolver-TM- System. DuPont shall notify Rosetta of the
desire to perform such upgrades for a determination by Rosetta of whether any
modifications or corrections must be made to the Resolver-TM- Software. DuPont
shall be free to purchase hardware upgrade components from whatever source it
desires. If DuPont desires to perform a Server upgrade during Stages 1 and 2
and desires to have Rosetta perform the upgrade, this will be classified as
"service" as set forth in Section 5.6. Shipping and installation of Server
components will be paid by DuPont.

          4.4 CONNECTION TO THE RESOLVER-TM- SYSTEM. For Stages 1 and 2, and
during Stage 3 for so long as the Server shall remain located on Rosetta's
premises, DuPont will be connected to the Resolver-TM- System using a secure
connection such as a virtual private network ("VPN") with the specifications
set forth in Appendix B or equivalent thereof.

          4.5 MATERIALS AND EQUIPMENT. Whenever materials, equipment, or third
party commercial software applications are specified or described in this
Agreement by using the name of a proprietary item or the name of a particular
supplier, the naming of the item is intended to establish the type, function and
quality required, and substitute materials or equipment may nonetheless be used;
provided that such materials or equipment are materially equivalent or equal to
that named. If Rosetta wishes to furnish or use a substitute item of material
or equipment, Rosetta must first certify that the proposed substitute will
perform at least as well the functions described in this Agreement and will be
of materially equal substance to that specified and be suited for the same use
as that specified. DuPont may require Rosetta to furnish, at Rosetta's expense,
reasonable amounts of additional data about the proposed substitute as required
to evaluate the substitution. DuPont will be allowed a reasonable time, not to
exceed [***], within which to evaluate each proposed substitute.

                  ARTICLE 5- DELIVERABLES AND RESPONSIBILITIES

*   Material has been omitted pursuant to a request for confidential treatment,
    and such material has been filed separately with the SEC.

                                      -9-
<PAGE>

          5.1 STAGE 1. Stage 1 shall begin with delivery of the Resolver-TM-
System with an Initial Feature Release of Resolver-TM- Software and shall end
upon the beginning of Stage 2. Rosetta anticipates delivery of the Resolver-TM-
System with an Initial Feature Release of the Resolver-TM- Software within
[***] of the Effective Date.

          5.1.1 STAGE 1 DELIVERABLES BY ROSETTA. For Stage 1, Rosetta will
provide the following:

          5.1.1.1 Delivery of the Resolver-TM- System described in Article 4
with an Initial Feature Release of the Resolver-TM- Software;

          5.1.1.2 User documentation for the Resolver-TM- System;

          5.1.1.3 [***] of training at Rosetta regarding use of the Initial
Feature Release for the Resolver-TM- Software for up to [***] individuals
from DuPont with transportation and lodging paid for by DuPont;

          5.1.1.4 Unlimited telephone and e-mail technical support for the
Resolver-TM- System between the hours of 9:00 a.m. and 5:00 p.m. Pacific Time
during Stage 1;

          5.1.1.5 Maintenance of the Resolver-TM- Server while it is located on
Rosetta's premises during Stage 1; and

          5.1.1.6 Installation at DuPont's location by Rosetta with the
cooperation of DuPont's staff of the VPN hardware and software necessary to
satisfy the minimum specifications set forth in Appendix B.

          5.1.2 STAGE 1 RESPONSIBILITIES OF DUPONT. For Stage 1, DuPont will
provide the following:

          5.1.2.1 Desktop computers located at a site to be determined by DuPont
for use with the Resolver-TM- System having the minimum specifications set forth
in Appendix C;

          5.1.2.2 Installation of Resolver-TM- Client Software onto the desktop
computers identified in Section 5.1.2.1;

          5.1.2.3 An internal computer network with l00BaseT network bandwidth
to each user's desktop CPU; and

          5.1.2.4 Feedback to Rosetta on the Resolver-TM- System pursuant to
Article 3.

          5.2 STAGE 2. Stage 2 shall begin with installation of the Second
Feature Release onto the Server by Rosetta and shall end upon the beginning of
Stage 3. Rosetta anticipates delivery of the Second Feature Release within three
(3) months after the Effective Date. Rosetta will discontinue support for the
Initial Feature Release delivered in Stage 1 upon the initiation of

*   Material has been omitted pursuant to a request for confidential treatment,
    and such material has been filed separately with the SEC.

                                      -10-
<PAGE>

Stage 2.

          5.2.1 STAGE 2 DELIVERABLES BY ROSETTA. For Stage 2, Rosetta will
provide the following:

          5.2.1.1 The Second Feature Release with the additional analytical
features set forth in Appendix A;

          5.2.1.2 Additional user documentation for the Resolver-TM- System;

          5.2.1.3 [***] of training at Rosetta regarding use of the Second
Feature Release for the Resolver-TM- Software for up to [***] individuals from
DuPont with transportation and lodging paid for by DuPont;

          5.2.1.4 Unlimited telephone and e-mail technical support for the
Resolver-TM- System between the hours of 9:00 a.m. and 5:00 p.m. Pacific Time
during Stage 2; and

          5.2.1.5 Maintenance of the Resolver-TM- Server while it is located on
Rosetta's premises during Stage 2.

          5.2.2 Stage 2 Responsibilities of DuPont. For Stage 2, DuPont will
provide the following:

          5.2.2.1 Installation of an upgrade for the Resolver-TM- Client
Software for the Second Feature Release onto the desktop computers identified
in Section 5.1.2.1; and

          5.2.2.2 Feedback to Rosetta on the Resolver-TM- System pursuant to
Article 3.

          5.3 STAGE 3. Stage 3 shall begin with installation of the
Feature-Complete Release of Resolver-TM- Software onto the Server. Rosetta
anticipates availability of a beta version of the Feature-Complete Release of
the R Resolver-TM- Software by January 2000. The Server with the Feature-
Complete Release software will then be delivered and installed at a site
specified by DuPont. Stage 3 will end one (1) year after initiation of
Stage 1. Rosetta will discontinue support for the Second Feature Release
delivered in Stage 2 upon the initiation of Stage 3.

          5.3.1 STAGE 3 DELIVERABLES BY ROSETTA. For Stage 3, Rosetta will
provide the following:

          5.3.1.1 Delivery and installation to a site specified by DuPont of the
Resolver-TM- System described in Article 4 and previously located at Rosetta's
premises with a beta version of the Feature-Complete Release;

          5.3.1.2 Additional user documentation for the Resolver-TM- System;

          5.3.1.3 [***] day of on-site training at DuPont regarding use of the
features provided by the Feature-Complete Release for up to [***] individuals
from DuPont

*   Material has been omitted pursuant to a request for confidential treatment,
    and such material has been filed separately with the SEC.

                                      -11-
<PAGE>

with the transportation and lodging for the Rosetta trainer paid for by Rosetta;

          5.3.1.4 Unlimited telephone and e-mail technical support for the
Resolver-TM- System between the hours of 9:00 a.m. and 5:00 p.m. Pacific Time
for one (1) year from initiation of Stage 3; and

          5.3.1.5 Upgrade protection for one (1) year from initiation of Stage
3. Upgrade protection shall mean that any new versions, service packs, or
patches of the Resolver-TM- Software will be made available to DuPont without
charge when available. Installation of a new version, service pack, or patch by
Rosetta under this upgrade protection provision shall be performed by DuPont or,
if DuPont wishes Rosetta to perform this service, it will be charged against the
service credit described in Section 5.6.

          5.3.2 STAGE 3 RESPONSIBILITIES OF DUPONT. For Stage 3, DuPont will
provide the following:

          5.3.2.1 Installation of an upgrade for the Resolver-TM- Client
Software for the Feature-Complete Release onto the desktop computers identified
in Section 5.1.2.1;

          5.3.2.2 Feedback to Rosetta on the Resolver-TM- System pursuant to
Article 3;

          5.3.2.3 An appropriate physical location for the Server at DuPont; and

          5.3.2.4 Network access by Rosetta to the Server located on DuPont's
premises to permit remote access support by Rosetta of the Resolver-TM- System
and Server Software if requested by DuPont.

          5.4 TECHNICAL SUPPORT. Technical support as used in this Agreement
means bug fixes, trouble shooting, and minor clarifications on use of the
Resolver-TM- System, and does not include any modifications to the Resolver-TM-
Software. Technical support does not include training or customization of the
Resolver-TM- Software.

          5.5 MAINTENANCE. Maintenance as used in Article 5 includes any work
done by Rosetta to keep the Server running properly while the Server is on
Rosetta premises including, if required, (1) Server database backups and
restores, (2) installation of Resolver-TM- Software updates and upgrades on the
Server, (3) labor associated with Server hardware repair, and (4) initial Server
hardware configuration. Maintenance as used in Article 5 does not include
installation of Resolver-TM- Client Software on DuPont's desktop computers,
installation of Server software after delivery of the Server to premises,
DuPont's or customization of the Resolver-TM- System for DuPont's needs.

          5.6 SERVICE. Time spent by Rosetta under this Agreement that does not
qualify as technical support or maintenance such as customization of the
Resolver-TM- System for DuPont's needs shall be considered service. At the
beginning of Stage 1, DuPont shall have a credit of [***] of service. This
credit of [***] is available to DuPont during Stages 1, 2, and 3 of this
Agreement and such credit shall expire at the end of Stage 3. Any time spent
by

*   Material has been omitted pursuant to a request for confidential treatment,
    and such material has been filed separately with the SEC.

                                      -12-
<PAGE>

Rosetta that exceeds the [***] of credited service shall be invoiced to DuPont
at [***]. In the event that a Rosetta employee or agent must make a service
call to DuPont's premises, reasonable expenses for travel and lodging of such
employee or agent will be paid by DuPont. Travel time, per se, shall not be
counted toward the credit.

                            ARTICLE 6 -- COMPENSATION

          6.1 DuPont shall pay directly to Rosetta [***] ("Agreed Price") plus
any applicable fees or taxes for the rights and licenses provided herein and
for the other goods and services provided hereunder. The Agreed Price shall be
guaranteed and it shall be non-refundable except as provided in Section 9.3.
[***] of the Agreed Price shall be paid within [***] of receipt of an invoice
by DuPont following the Effective Date, [***] of the Agreed Price shall be
paid within [***] days of receipt of an invoice by DuPont for Stage 1
deliverables described in Sections 5.1.1.1, 5.1.1.2, 5.1.1.3, and 5.1.1.6,
and the balance of the Agreed Price shall be paid within [***] days of
receipt of an invoice by DuPont of Stage 3 deliverables described in Sections
5.3.1.1 and 5.3.1.2.

          6.2 The amount set forth in Section 6.1 is comprised of the
following:

          [***]

          6.3 In the event DuPont shall from time to time elect to extend the
term of Rosetta's obligations pursuant to Section 7.1.2, DuPont shall, upon each
such election, pay an amount not to exceed [***] of the then existing list
price of the Resolver-TM- Software license.

                 ARTICLE 7 - TERM AND TERMINATION OF THE PROGRAM

          7.1      TERM.

          7.1.1 The term ("Term") of this Agreement shall begin on the
Effective Date and shall terminate upon the earlier of (1) one (1) year after
the initiation of Stage 3, (2) the date to which this Agreement is extended
in accordance with Section 7.1.2, or (3) the date this Agreement is
terminated pursuant to Section 7.2. Provisions of this Agreement which, by
their nature, should survive termination such as, but not limited to Sections
3.1.2, 3.1.4, 3.6, 3.8, 3.9, or the

*   Material has been omitted pursuant to a request for confidential treatment,
    and such material has been filed separately with the SEC.

                                      -13-
<PAGE>

obligations of Articles 8 shall survive termination of this Agreement.

          7.1.2. DuPont will have the right and option, exercisable in
writing at any time during the three (3) month period immediately preceding
the then current date on which this Agreement is to expire, to notify Rosetta
that DuPont elects to extend the term of Rosetta's obligations to provide
Software upgrades, and maintenance and support services related to the
Resolver-TM- System for one additional year. In the event of any such
election by DuPont, DuPont shall thereupon promptly pay to Rosetta the amount
set forth in Section 6.3 hereof. The Parties acknowledge and agree that they
will negotiate in good faith an amendment and restatement to this Agreement
upon the first exercise by DuPont of its election to extend Rosetta's
obligations hereunder, taking into account completion of Stages 1, 2, and 3,
and incorporating such terms and conditions that are ordinary and customary
for maintenance and support contracts for software similar in scope and
complexity to the Resolver-TM- Software.

          7.2 NOTICE OF DEFAULT, CURE PERIOD, AND TERMINATION. If a Party
defaults in the performance of its obligations under this Agreement, the
other Party may send a written notice to the defaulting Party describing such
default or defaults. The defaulting Party shall cure the default or defaults
described in the notice within thirty (30) days after the giving of such
notice, unless it is not technically feasible to cure the default within such
thirty (30) days, in which case the defaulting Party (i) shall prepare and
submit to the non-defaulting Party within such thirty (30) days period a
mutually agreeable plan to cure the default and (ii) shall proceed to cure
the default under such plan, PROVIDED, HOWEVER, in the event the default is
in respect of DuPont's obligations under Section 6.1 hereof, such default
shall be cured within seven (7) days after the giving of such notice. If the
Parties do not agree upon a plan to cure the default, or if the Party in
default fails to cure its default or defaults within the time period or
periods specified in the preceding sentence, the other Party may terminate
the Program by delivering a notice of termination to the defaulting Party.

                          ARTICLE 8 -- CONFIDENTIALITY

         8.1 EXCHANGE AND CREATION OF CONFIDENTIAL INFORMATION. The Parties
anticipate the need to disclose, exchange, and create Confidential Information
during the Program. The Parties also recognize that an employee, consultant or
representative of a Party in visiting the premises of another Party may be given
access to areas of the premises of such other Party where such employee,
consultant or representative may observe or overhear Confidential Information
that has not been marked or stated to be confidential. As used in this Article
8, the Party that discloses Confidential Information to the other Party as
described in Section 1.4 shall be called the Disclosing Party with respect to
such information, and the Party that receives Confidential Information from the
Disclosing Party as described in Section 1.11 shall be called the Receiving
Party with respect to such information. If an employee, consultant, or
representative of one Party creates or develops information jointly or in
conjunction with an employee, consultant, or representative of another Party,
and if either Party notifies the other Party that it has designated such
information as Confidential Information or a reasonable person would treat such
information as confidential or proprietary, the information will be considered
and treated as Confidential Information hereunder; each Party then shall have
the rights of a Disclosing Party and the responsibilities of a Receiving Party.

*   Material has been omitted pursuant to a request for confidential treatment,
    and such material has been filed separately with the SEC.

                                      -14-
<PAGE>

          8.2 MARKING, DESIGNATION, AND TRANSMITTAL OF CONFIDENTIAL
INFORMATION. Each Party that wishes to protect its Confidential Information
shall take precaution (a) to mark any document containing Confidential
Information with an appropriate legend, such as "Confidential" or
"Proprietary" or other similar marking, before giving it to another Party,
(b) to advise the other Party at the time of an oral or visual disclosure of
Confidential Information that such information is confidential, (c) to
prepare a written summary of all such Confidential Information that is
disclosed orally or visually and (d) to send such summary to the other Party
within thirty (30) days of the oral or visual disclosure confirming that such
information previously disclosed orally or visually is to be considered
confidential. When transmitting Confidential Information via encrypted email,
the Disclosing Party shall send a copy of the encrypted email message to the
Program Contact for the Receiving Party and a copy of the encrypted email
message to its own Program Contact. The Program Contact for each Party shall
maintain copies of all encrypted email messages containing Confidential
Information that are sent and that are received by such Party for a period of
five (5) years from the date of receipt. This provision shall not be read to
limit the definition of Confidential Information set forth in Section 1.2.

          8.3 ACKNOWLEDGEMENT OF TRADE SECRETS. DuPont acknowledges that the
Software contains valuable trade secrets and confidential information owned by
Rosetta including, but not limited to, the development status of the Software,
the functionality of the Software, the appearance, content and flow of the
Software's user interface, the content of the Software's documentation and other
information, and data related and ancillary to the Software. All of such trade
secrets and information are considered Confidential Information as that term is
used in this Agreement.

          8.4 PROTECTION OF CONFIDENTIAL INFORMATION. Each Receiving Party shall
use at least the same degree of care in protecting the Disclosing Party's
Confidential Information as it uses to protect its own Confidential Information.
Each Party represents that it maintains a reasonable system to protect its own
Confidential Information and the Confidential Information that it receives from
others. Each Party further represents and warrants to the other Party that its
employees, consultants, and representatives who will perform any work under this
Agreement and who will have access to Confidential Information will be subject
to a valid, binding and enforceable agreement to maintain the confidentiality of
Confidential Information and to fulfill the obligations with respect to
Confidential Information set out in this Article. Each Party shall take
reasonable precaution to prevent employees, consultants, or representatives of
another Party or third parties from (a) receiving any document containing
Confidential Information that has not been marked with an appropriate legend and
(b) observing or overhearing Confidential Information that has not been marked
or stated to be confidential.

          8.5 RESTRICTIONS ON DISCLOSURE OF CONFIDENTIAL INFORMATION. The
Receiving Party shall not disclose any Confidential Information that it received
from the Disclosing Party, without prior written permission of the Disclosing
Party, to any person other than to its employees, and consultants, and
representatives who have a need to know such information to carry out their
duties or activities in connection with the Program or as otherwise authorized
by this Agreement; provided, however, that any consultant of the Receiving Party
to whom

*   Material has been omitted pursuant to a request for confidential treatment,
    and such material has been filed separately with the SEC.

                                      -15-
<PAGE>

Confidential Information is disclosed, must be obligated by written agreement to
give the same protection to the Confidential Information as is provided herein,
or have a similar obligation to the Receiving Party to maintain confidential
information in confidence. If a Receiving Party is required by judicial or
administrative process to disclose Confidential Information of the Disclosing
Party, such Receiving Party shall notify such Disclosing Party in writing and
allow the Disclosing Party reasonable opportunity to oppose such process or
limit the disclosure of Confidential Information.

          8.6 EXCLUSIONS. A Receiving Party may disclose information even though
it may be considered Confidential Information of a Disclosing Party in
connection with a judicial proceeding requiring such disclosure provided that
the Disclosing Party has adequate notice of such proceeding and an opportunity
to object to or limit the disclosure, and provided that the disclosure of
Confidential Information is limited to what is required as mutually determined
by the Receiving Party and the Disclosing Party.

          8.7 TREATMENT OF PREVIOUS DISCLOSURES. If the Parties have
communicated Confidential Information pertinent to the Early Access Program to
each other pursuant to Confidential Disclosure Agreements and/or Non-Disclosure
Agreements, prior to the Effective Date, all such Confidential Information
transmitted, received, or exchanged will be governed by this Agreement, which
shall supersede any such other agreements in their application to Confidential
Information relating to the Program.

          8.8 SURVIVAL AND EXPIRATION. The obligations of non-disclosure and
restrictions on use contained in this Article 8 shall survive for a period of
five (5) years from the expiration or termination of the remaining provisions
of this Agreement.

                   ARTICLE 9 -- REPRESENTATIONS AND WARRANTIES

          9.1 WARRANTIES BY EACH PARTY. Each Party represents and warrants to
the other Party that:

          9.1.1 such Party has full corporate right, power, and authority to
enter into this Agreement and to perform the acts required of it hereunder;

          9.1.2 the execution of this Agreement by such Party, and the
performance by such Party of its obligations and duties hereunder do not and
will not violate any agreement to which such Party is a party or by which it is
otherwise bound;

          9.1.3 when executed and delivered by such Party, this Agreement will
constitute the legal, valid, and binding obligation of such Party, enforceable
against such Party in accordance with its terms; and

          9.1.4 such Party acknowledges that the other Party makes no
representations, warranties, or agreements related to the subject matter of this
Agreement that are not expressly provided for in this Agreement.

*   Material has been omitted pursuant to a request for confidential treatment,
    and such material has been filed separately with the SEC.

                                      -16-
<PAGE>

          9.2 WARRANTY OF Y2K COMPLIANCE. Rosetta warrants that the
Resolver-TM- Software is Year 2000 Compliant. "Year 2000 Compliant" shall mean
that dates before, on, or after January 1, 2000, encountered and/or processed
by the Resolver-TM- Software will be correctly recognized, calculated, sorted,
stored, displayed, and/or otherwise processed within the Resolver-TM- Software.
This warranty shall not be subject to any disclaimer or exclusion of warranties
made in this Agreement pursuant to Section 9.3, except that this warranty shall
not be construed to apply to any of the other components of the Resolver-TM-
System including, but not limited to, the hardware and other software, such as
Server software which is not Resolver-TM- Server Software and third party
software, provided under this Agreement.

          9.3 ACKNOWLEDGMENT BY DUPONT; DISCLAIMER OF OTHER WARRANTIES.
DuPont and Rosetta agree that the Software is provided "AS IS" and that
Rosetta makes no warranty as to the Software. DuPont acknowledges and agrees
that (i) the Software is not a product that has been commercially released
for sale by Rosetta, (ii) the Software is not in final form and may contain
errors, design flaws, or other problems, (iii) the Software is not expected
to function error-free upon installation, and it is expected and anticipated
that further testing, modification, and development will be necessary to make
the Software fully functional, (iv) it may not be possible to make the
Software fully functional, (v) use of the Software may result in unexpected
results, loss of data, project delays, or other unpredictable damage or loss
to DuPont and (vi) Rosetta is under no obligation to release and/or offer for
sale the commercial version of the Software, and Rosetta has the right to
unilaterally abandon development of the Software, all at any time and in each
case without any obligation or liability to DuPont, provided, however, that
if Rosetta abandons development of the Software during a one (1) year period
beginning with the initiation of Stage 1, Rosetta shall refund to DuPont the
full amount paid to date by DuPont excluding the amounts paid and owed under
Sections 6.2.2, 6.2.3, 6.2.4, and 6.2.5. ROSETTA DISCLAIMS ALL WARRANTIES,
EXPRESS OR IMPLIED, OTHER THAN THOSE EXPRESSLY SET FORTH IN SECTIONS 9.1 AND
9.2 HEREOF INCLUDING, BUT NOT LIMITED TO, ANY WARRANTY OF NON-INFRINGEMENT,
PATENTABILITY, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, WITH
RESPECT TO THE RESOLVER-TM- SYSTEM AND RESOLVER-TM- SOFTWARE INCLUDING, BUT
NOT LIMITED TO, ALL HARDWARE AND ALL OTHER SOFTWARE SUCH AS SERVER SOFTWARE
AND THIRD PARTY SOFTWARE PROVIDED UNDER THIS AGREEMENT. FURTHERMORE, ROSETTA
EXPRESSLY DISCLAIMS THE WARRANTY MADE IN SECTION 9.2 WITH RESPECT TO THE
COMPONENTS OF THE RESOLVER-TM- SYSTEM OTHER THAN THE RESOLVER-TM- SOFTWARE
INCLUDING, BUT NOT LIMITED TO, ALL HARDWARE AND ALL OTHER SOFTWARE SUCH AS
SERVER SOFTWARE WHICH IS NOT RESOLVER-TM- SERVER SOFTWARE AND THIRD PARTY
SOFTWARE PROVIDED UNDER THIS AGREEMENT.

            ARTICLE 10 -- DISCLAIMERS AND LIMITATION OF LIABILITIES

         10.1 INFRINGEMENT OF INTELLECTUAL PROPERTY RIGHTS. Rosetta disclaims
any representation or warranty that the technology, information, know-how, data,
software, user documentation, or processes disclosed or furnished to DuPont or
conceived, developed, or used in the Program does not or will not infringe any
Intellectual Property Rights of any third party

*   Material has been omitted pursuant to a request for confidential treatment,
    and such material has been filed separately with the SEC.

                                      -17-
<PAGE>

who is not a party to this Agreement. Each Party shall, however, notify the
other Party promptly in writing if such Party has a reasonable basis for
believing that any such technology, information, know-how, data, or process, or
that any product that incorporates any such technology or that is made using any
such process would infringe any Intellectual Property Right of a party who is
not a party to this Agreement. This Section 10.1 shall not be interpreted to
place an affirmative duty on any Party to perform a patent search or other
review of intellectual property of a third party to determine if it is
infringing any Intellectual Property Right of another Party or a party who is
not a Party.

          10.2 LIMITATION OF LIABILITIES. NO PARTY SHALL UNDER ANY CIRCUMSTANCES
BE LIABLE TO ANOTHER PARTY FOR INDIRECT, INCIDENTAL, SPECIAL, OR CONSEQUENTIAL
DAMAGES, LOSSES, LIABILITIES, COSTS, OR EXPENSES (INCLUDING, BUT NOT LIMITED TO,
LOSS OF PROFITS, GOODWILL, REVENUE, OR BUSINESS) RESULTING FROM OR IN ANY WAY
RELATED TO THIS AGREEMENT, OR TERMINATION OF THIS AGREEMENT, OR ARISING OUT OF
OR ALLEGED TO HAVE ARISEN OUT OF (I) BREACH OF THIS AGREEMENT, (II) THE FAILURE
BY ANY PARTY TO DEVOTE THE RESOURCES OR EFFORT SPECIFIED IN THIS AGREEMENT,
(III) THE FAILURE BY ANY PARTY TO COMPLY WITH THE EXPRESS CONDITIONS SPECIFIED
IN THIS AGREEMENT, OR (IV) ANY EVENT RELATED TO THE MAKING OR PERFORMANCE OF
THIS AGREEMENT. THIS LIMITATION APPLIES REGARDLESS OF WHETHER SUCH DAMAGES ARE
SOUGHT BASED ON BREACH OF CONTRACT, BREACH OF WARRANTY, NEGLIGENCE, STRICT
LIABILITY, OR ANY OTHER LEGAL OR EQUITABLE THEORY.

          10.3     INFRINGEMENT.

          10.3.1 DuPont and Rosetta agree that Rosetta will indemnify DuPont
against and will defend, at its own expense, all proceedings, suits, and claims
against and/or affecting DuPont or any of its officers, directors, or employees
alleging the infringement, breach or violation of any Intellectual Property
Rights of any third party covering, or alleged to cover, the Software, in the
form furnished or as subsequently modified by Rosetta. Rosetta agrees to defend
any such proceeding, suit, or claim, and to pay all costs, fees, and expenses
including, without limitation, all reasonable attorneys' fees and other costs,
incurred by DuPont and its officers, directors, agents or employees in
connection with the defense of any such proceeding, suit, or claim, provided
that:

                   (i) Rosetta will be given written notice of all claims of any
          such infringement or violation and of any suits or claims brought or
          threatened against DuPont;

                   (ii) Rosetta will be given full authority to assume control
          of the defense thereof through its own counsel at its sole expense but
          will not compromise or settle any suits or claims without the express
          prior written consent of DuPont, provided that such consent will not
          be unreasonably withheld or delayed;

                   (iii) DuPont will reasonably cooperate with Rosetta in the
          defense of such


                                      -18-
<PAGE>

          proceeding, suit, or claim at Rosetta's sole expense; and

                   (iv) the total expense that Rosetta shall be obligated to
          bear and pay under this Section 10.3.1 shall not exceed [***], the
          amount of the Resolver-TM- Software license paid by DuPont.

                   10.3.2 DuPont will indemnify Rosetta against all liabilities
          and costs, including reasonable attorneys' fees, for defense and
          settlement of any and all claims against DuPont or Rosetta in the
          event an allegation of infringement or violation of Intellectual
          Property Rights of a third party is caused by (i) modification of the
          Software by DuPont, (ii) any infringement caused by DuPont's use or
          maintenance of the Software which conflicts with the terms and
          conditions of this Agreement, and (iii) DuPont's willful use of the
          Software after receipt of notice of infringement.

                   ARTICLE 11 -- DISPUTES BETWEEN THE PARTIES

         11.1 SCOPE AND PURPOSE OF THIS ARTICLE. The purpose of this Article
11 is to set forth the procedures pursuant to which the Parties intend in
good faith to resolve any and all disagreements and disputes between the
Parties arising under or related to this Agreement or its making, or the
activities of the Parties in connection with the Program (collectively,
"Disputes"). The Parties shall follow these procedures fully and exhaustively
before initiating any litigation to resolve any Dispute. However, nothing
herein shall prevent a Party from filing suit seeking equitable relief
(mandatory or prohibitive) to prevent what it perceives as imminent,
irreparable harm or to compel a Party to specifically perform in accordance
with this Article 11; provided, that if such relief is granted, the Parties
will stipulate that any further proceedings in such suit shall be stayed
pending the completion of the procedures set forth herein. These procedures
do not apply to any claims by unrelated parties. The Parties stipulate that
the running of any applicable statute of limitations shall toll effective
upon the first notice given under Section 11.2 until thirty (30) days after
the completion of the process provided in Section 11.3.

          11.2 NOTICE OF DISPUTE. A Party that perceives a Dispute with the
other Party subject to this Article 11 may notify the other Party in writing
of any Disputes that it wants resolved ("Notifying Party"). The Notifying
Party shall include in the notice a detailed statement of the Disputes and a
summary of the evidence and arguments supporting the position asserted. The
other Party ("Responsive Party") shall respond to the notice within ten (10)
business days after receipt thereof and may include with its response a
cross-notice of any Disputes that the Responsive Party wants resolved. If a
Responsive Party raises an additional Dispute, the Notifying Party shall then
respond to such cross-notice within seven (7) business days after receipt of
the Responsive Party's cross-notice. Notwithstanding Section 3.9, all
notices, cross-notices and responses shall be in writing and sent by
facsimile with a confirming copy sent by first class mail.

          11.3 UNAIDED NEGOTIATIONS BETWEEN THE PARTIES. Initially the
Program Contacts and the General Managers of the business unit participating
in the Program shall meet at a mutually acceptable time and place within
fifteen (15) businsss days after delivery of the final response, and
thereafter as often as they deem necessary, to exchange relevant information
and attempt to

*   Material has been omitted pursuant to a request for confidential treatment,
    and such material has been filed separately with the SEC.

                                      -19-
<PAGE>

resolve the dispute. If the matter is not resolved by these Managers within
thirty (30) business days of receipt of the Notifying Party's first written
notice, or if such Managers fail to meet within fifteen (15) business days
after delivery of the final response, the Dispute shall be referred to the
senior executives who have responsibility for the respective organizations
involved in the Dispute and who have full and final authority to settle the
Dispute. These senior executives shall likewise meet, with or without the
respective Business Managers and Program Managers, at a mutually acceptable
time and place within ten (10) business days after such referral, and
thereafter as often as they reasonably deem necessary, to exchange
information and attempt to resolve the Dispute. All meetings to be held under
this Section 11.3 may be held in person, or may be held by means of telephone
or similar communications equipment.

          11.4 LITIGATION. If, after completing the above procedures set out in
Section 11.3, the Parties involved in the Dispute have not resolved fully all
Disputes, any Party involved in an unresolved Dispute may file suit in a United
States District Court if the dispute involves a federal question and the other
requirements for federal jurisdiction are met, or in a State Court if the
dispute involves only non-federal questions or the requirements for federal
jurisdiction are not met. The venue for a suit filed by DuPont shall be Seattle,
Washington, and the venue for a suit filed by Rosetta shall be Wilmington,
Delaware.

          11.5 GOVERNING LAW. This Agreement and all questions, claims,
disputes, remedies or procedural matters relating to Disputes under this
Agreement shall be interpreted in accordance with and governed exclusively by
the laws of the State of Delaware, U.S.A., without regard to the principles of
conflicts of law.

                           ARTICLE 12 -- MISCELLANEOUS

          12.1 LEGAL STATUS OF THE PARTIES AND THE PROGRAM. Each Party is an
independent contractor and will act as such in accordance with the terms of this
Agreement in performing its respective obligations under this Agreement. This
Agreement is not intended to create, nor shall the activities of the Parties or
the Program be construed to create, a joint venture, partnership, or other
formal business organization. No Party shall represent to any third party that
this Agreement creates, or that the Program is, a joint venture, partnership, or
other formal business organization. Nothing herein shall be construed as
providing for the sharing of profits or losses. Except as expressly provided
herein, no Party can bind any other Party or create any relationship of
principal or agent. Except as expressly provided herein, nothing in this
Agreement shall grant to any Party the right to make future commitments of any
kind for or on behalf of the other Party. No employee of one Party shall be
deemed to be the employee of another Party by virtue of this Agreement. No Party
shall have any liability for any activities of any other Party by virtue of this
Agreement.

          12.2 NO THIRD PARTY BENEFICIARIES. This Agreement is intended for the
sole benefit of the Parties hereto, and unless expressly provided herein, no
rights or powers shall arise hereunder in favor of any third party.

          12.3 FORCE MAJEURE. The failure of any Party to perform hereunder as a
result of governmental action, laws, orders, or regulations, or as a result of
events, such as war, acts of

*   Material has been omitted pursuant to a request for confidential treatment,
    and such material has been filed separately with the SEC.

                                      -20-
<PAGE>

public enemies, fires, floods, earthquakes, acts of God or any causes of like
kind beyond the reasonable control of such Party is excused for so long as such
cause exists, but only to the extent such failure is caused by such law, order,
regulation, or event.

          12.4 EXPORTS. Each Party hereto shall be responsible for ensuring its
compliance with the laws and regulations of the United States government
relating to the export of goods and technology from the United States, and the
Party receiving technical information from another Party hereby agrees to comply
fully with the United States Export Administration Act and regulations
promulgated thereunder from time to time by the United States government with
respect to that technical information.

          12.5 ASSIGNMENT. Neither Party may assign this Agreement nor any of
its rights or obligations hereunder without the prior written consent of the
other Party, except that a Party may assign its rights and obligations, without
the consent of the other Party, as part of an assignment of the entire
Agreement, in connection with (i) a change of the state of incorporation of a
Party, or (ii) a merger of a Party into its parent corporation, (iii) the
spin-out of the business with which this Agreement is associated into a wholly
owned corporation of a Party, (iv) the spin-out of the business with which this
Agreement is associated into a separate entity, (v) the subsequent merger of any
such wholly owned corporation or separate entity into another entity or (vi) the
sale of substantially all the assets of the business unit with which the
agreement is associated. Any permitted assignee shall assume all obligations of
its assignor under this Agreement. No assignment shall relieve any Party of
responsibility for the performance of any accrued obligation that such Party
then has under this Agreement without prior written consent of the other Party.
Any purported assignment by one Party in violation of this Section shall be
voidable by any other Party.

          12.6 RULES OF CONSTRUCTION AND INTERPRETATION. This Agreement shall be
construed and fairly interpreted in accordance with its terms, without any
strict construction in favor of or against either Party. Ambiguities shall not
be interpreted against the drafting Party. Any ambiguities in this Agreement
shall be interpreted in accordance with the objectives stated in the Recitals.
In construing or interpreting this Agreement, the word "or" shall not be
construed as exclusive, and the word "including" shall not be limiting. The use
of the singular or plural form shall include the other form and the use of the
masculine, feminine or neuter gender shall include the other genders. All
captions and headings in this Agreement are for convenience only and shall not
be considered as substantive parts of this Agreement or determinative in the
interpretation of this Agreement.

          12.7 AMENDMENT AND WAIVER. Any provision of this Agreement may be
amended or waived only with the written consent of the parties. Any amendment or
waiver effected in accordance with this Section shall be binding upon the
parties and their respective successors and assigns.

          12.8 SEVERABILITY. If one or more provisions of this Agreement are
held to be unenforceable under applicable law, the Parties agree to renegotiate
such provision in good faith, in order to maintain the economic position enjoyed
by each Party as close as possible to that under the provision rendered
unenforceable. In the event that the Parties cannot reach a mutually


                                      -21-
<PAGE>

agreeable and enforceable replacement for such provision, then (i) such
provision shall be excluded from this Agreement, (ii) the balance of the
Agreement shall be interpreted as if such provision were so excluded and (iii)
the balance of the Agreement shall be enforceable in accordance with its terms.

          12.9 INTEGRATION. This Agreement, together with the Appendices
identified below, contains the entire understanding of the Parties as it relates
to the subject matter hereof and supersedes any prior agreements or
understandings between or among the Parties as to this subject matter:

          12.9.1 Appendix A -- Features for Resolver-TM- Software for Stages 1,
2, and 3

          12.9.2 Appendix B -- Virtual private network specification

          12.9.3 Appendix C -- Specification of desktop computers to be used by
DuPont

          12.10 DISPARAGEMENT. DuPont agrees not to disparage or make negative
comments about Rosetta's personnel, the Resolver-TM- System, or services
provided by Rosetta.

          12.11 COUNTERPARTS. This Agreement may be signed in any number of
counterparts, each of which shall be deemed an original, but all of which shall
constitute one and the same instrument.

                            [Signature page follows]


                                      -22-
<PAGE>

          IN WITNESS WHEREOF, the parties hereto have caused this Agreement to
be executed by their duly authorized representatives on the date written below.

DUPONT PHARMACEUTICALS COMPANY               ROSETTA INPHARMATICS, INC.

By /S/                                       By
  ----------------------------                 ----------------------------
                                                      John J. King, II

   DIRECTOR PROCUREMENT                      SR. VICE PRESIDENT
------------------------------               ----------------------------
              Title                                      Title

   10/07/99                                  SEPTEMBER 30, 1999
----------------------------                 ----------------------------
               Date                                        Date


                                      -23-
<PAGE>

      APPENDIX A -- FEATURES OF RESOLVER-TM- SOFTWARE FOR STAGES 1,2, AND 3 7

STAGEL:  FEATURES IN INITIAL FEATURE RELEASE

IMAGE VIEWER
View and interpret images representing primary data for a given profiling
technology.

PLOT VIEWER
A flexible plotting engine for experiments, profiles, and genes with powerful
analytical features to help decision making and the presentation of results.

TABLE VIEWER
View expression data for experiments, profiles, and genes in a customizable
spreadsheet format. Sort & export data for use in other applications. Rearrange,
show, or hide columns to tailor the display to the user's needs.

CORRELATION PLOT VIEWER
Using the Correlation Plot Viewer, pairs of genes, profiles, or experiments in
the user's gene expression database can be quickly compared.

SYNCHRONIZATION
Synchronization refers to the Resolver application's ability to share selected
data among many different tools. Use synchronization to quickly and effectively
visualize and analyze data identified in one tool using a second tool.

ROLE-BASED SECURITY SYSTEM
The role-based security system delivered with the Resolver application provides
row-level access control for all cell lines, tissues, hybridizations, profiles,
and experiments.

PERSISTENT USER PROFILES
Persistent user profiles allow all users to set preferences for the way they use
the Resolver application --table configuration, statistical cutoffs,
highlighting, etc.--and have those same options in place the next time they use
the Resolver, even if the system is accessed using another client machine.

ANNOTATION MANAGERS FOR CELL LINES/TISSUES, NUCLEIC ACID PREPARATIONS (PREPS),
AND HYBRIDIZATIONS (HYBS) The Resolver application includes spreadsheet-like
interfaces and forms for scientists to effectively manage cell lines and
tissues, RNA samples, hybridizations, and experiments tracked within the system.

QUALITY STATISTICS
The Resolver application includes easy-to-understand quality statistics,
including P-values on every gene expression measurement. Using these statistics,
even the subtlest transcriptional responses can be characterized by repeating
expression profiles and combining them into statistically averaged experiments
within the Resolver application.

STAGE 2. SECOND FEATURE RELEASE INCLUDES ALL FEATURES IN INITIAL FEATURE
         RELEASE, PLUS:

ROSETTA ARRAY SEARCH TOOL ("ROAST")
Use ROAST (Rosetta Array Search Tool), to compare one gene, experiment, or
expression profile against others in the database. This tool is analogous to the
BLAST sequence analysis tool.

USER-DEFINED BIOSETS
Use the BioSets features in the Resolver application to group and store
collections of genes or experiments of interest and perform set manipulation on
these groups. Add annotation and comments to BioSets and, if desired, share them
collaboratively with other Resolver users.


<PAGE>

COMMENT SYSTEM
An easy-to-use comment system allows users to add or view comments about genes,
experiments, expression profiles, or BioSets and even respond to comments made
by other users. View comments in hierarchical newsgroup-like format or in table
format.

INSTALINK-- PRODUCTIVITY LINK SYSTEM
Use InstaLink to quickly access bioinfonnatics resources within the Resolver
application, on the World Wide Web, or on the user's Intranet that aid in the
analysis of a particular datapoint within the application. Medline, Entrez, and
other databases can be searched with two clicks using this feature. The user can
add personalized productivity links to Internet and Intranet sites.

STAGE 3. FEATURE-COMPLETE RELEASE INCLUDES ALL FEATURES IN SECOND
                   FEATURE RELEASE, PLUS:

CLUSTER ANALYSIS ENGINE
Analyze gene expression data, and identify co-regulated gene sets and classes of
similar compounds using a high-performance, flexible cluster analysis engine.

CLUSTER TREE VIEWER
Visualize and analyze data from the Cluster Analysis Engine in a compact,
convenient hyperbolic display. Search for genes or experiments of interest, and
zoom, magnify, move, or rotate trees to identify clusters of interest.

SERVER ADMINISTRATION TOOLS
Use these configuration interfaces and control panels to administer and
customize the Resolver application.

*   Resolver is a trademark of Rosetta Inphannatics, Inc.


<PAGE>

      APPENDIX B -- VIRTUAL PRIVATE NETWORK SPECIFICATIONS

    [***]

Electrical

    -  Line Voltage: 100/115/230 VAC
    -  Frequency: 50/60 Hz
    -  Maximum power consumption: 5 amps

Physical

    -  19-rack mount kit
    -  Height: 6" (15.24cm)
    -  Width: 16" (40.64cm)
    -  Length: 16.5" (41.94cm)

Environmental

    -  Operating temperature: 41 degrees, 104 degrees F (5 degrees, 40
       degrees C)
    -  Storage temperature: -40 degrees -158 degrees F (-40 degrees 70
       degrees C)
    -  Relative humidity: 10% 80%, noncondensing

2.  This VPN hardware is configurable to balance security with speed.
Configuration of this hardware to maximum security levels will negatively
affect performance of the Resolver-TM- System available to DuPont.




*   Material has been omitted pursuant to a request for confidential treatment,
    and such material has been filed separately with the SEC.

<PAGE>

      APPENDIX C -- DESKTOP COMPUTER MINIMUM SPECIFICATIONS

Minimum Specifications

    300 MHz Pentium II or III Compatible processor
    128 Megabytes of RAM
    20 Megabytes free hard drive space
    Windows 98 or Windows NT Workstation 4.0 SP3+
    Minimum number of displayable colors: 65536
    Minimum monitor resolution: 1024 x 768




*   Material has been omitted pursuant to a request for confidential treatment,
    and such material has been filed separately with the SEC.